Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of dual versus triple antiemetic prophylaxis during trastuzumab deruxtecan for unresectable recurrent gastric cancer
jRCTs031200336Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aprepitant, palonosetron and dexamethasone in Nausea and Vomiting, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Complete response rate. Started Apr 2021; status: completed.
02
Drugs
aprepitantpalonosetrondexamethasone
03
Conditions
Nausea and Vomitinggastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031200336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200336.